ignaseclant (NMD670)
Charcot-Marie-Tooth disease (CMT)
Key Facts
About NMD Pharma
NMD Pharma is a private, clinical-stage biotechnology company pioneering a novel approach to treating neuromuscular diseases by targeting skeletal muscle-specific ClC-1 ion channels. Founded in 2015 and headquartered in Aarhus, Denmark, the company has built a proprietary muscle electrophysiology platform to develop small molecule therapies aimed at improving muscle strength and reducing fatigue. With a lead candidate, ignaseclant, in Phase 2 trials for multiple indications and approximately $180 million raised from investors, NMD is advancing a pipeline targeting rare neuromuscular and broader age-related conditions with significant unmet need.
View full company profileAbout NMD Pharma
NMD Pharma is a private, clinical-stage biotechnology company pioneering a novel approach to treating neuromuscular diseases by targeting skeletal muscle-specific ClC-1 ion channels. Founded in 2015 and headquartered in Aarhus, Denmark, the company has built a proprietary muscle electrophysiology platform to develop small molecule therapies aimed at improving muscle strength and reducing fatigue. With a lead candidate, ignaseclant, in Phase 2 trials for multiple indications and approximately $180 million raised from investors, NMD is advancing a pipeline targeting rare neuromuscular and broader age-related conditions with significant unmet need.
View full company profileAbout NMD Pharma
NMD Pharma is a private, clinical-stage biotechnology company pioneering a novel approach to treating neuromuscular diseases by targeting skeletal muscle-specific ClC-1 ion channels. Founded in 2015 and headquartered in Aarhus, Denmark, the company has built a proprietary muscle electrophysiology platform to develop small molecule therapies aimed at improving muscle strength and reducing fatigue. With a lead candidate, ignaseclant, in Phase 2 trials for multiple indications and approximately $180 million raised from investors, NMD is advancing a pipeline targeting rare neuromuscular and broader age-related conditions with significant unmet need.
View full company profile